Form 4: Atara Biotherapeutics Director Pascal Touchon Granted Restricted Stock Units

Atara Biotherapeutics, Inc. Director Pascal Touchon was granted 7,828 shares of common stock in the form of restricted stock units on June 10, 2025.

Summary

• Pascal Touchon, a Director of Atara Biotherapeutics, Inc. (ATRA), was granted 7,828 shares of common stock.
• The transaction occurred on June 10, 2025, and was reported via a Form 4 filing on June 12, 2025.
• These shares were acquired at a price of $0, indicating they are restricted stock units (RSUs) as part of compensation.
• Following this transaction, Mr. Touchon's beneficial ownership stands at 77,955 shares of common stock.
• The restricted stock units are set to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, contingent on Mr. Touchon's continuous service to the company.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive sign of alignment between management/board and shareholders, indicating commitment and incentivizing long-term performance. It's a standard compensation practice that generally contributes to stable governance.

Positives

• The grant of restricted stock units to Director Pascal Touchon aligns his interests with long-term shareholder value, as vesting is contingent on continued service and future stock performance.
• This compensation method is a common practice for retaining and incentivizing key board members, demonstrating the company's commitment to its leadership.

Future Outlook

The vesting schedule for the restricted stock units indicates a commitment to retaining Director Pascal Touchon through at least June 10, 2026, or until the next annual meeting, aligning his incentives with the company's future performance and strategic objectives.

Industry Context

This transaction is a routine insider compensation event common in the biotechnology industry, where equity grants are frequently used to attract and retain experienced directors and executives. This practice aligns their long-term interests with the company's success in a capital-intensive and research-driven sector, fostering stability and commitment at the board level.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard compensation practice across the biotechnology and pharmaceutical industries, comparable to similar equity incentive plans at companies like Biogen Inc. (BIIB) or Gilead Sciences, Inc. (GILD).
• These companies frequently use RSUs to incentivize and retain board members and executives, linking their compensation to the company's stock performance.
• The $0 acquisition price is typical for RSU grants, reflecting their nature as compensation rather than a cash purchase, which is consistent with industry benchmarks for equity-based awards.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value through equity ownership, potentially fostering more diligent oversight and strategic decision-making.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this specific filing, as it pertains solely to director compensation.

Next Steps

• The restricted stock units granted to Pascal Touchon are expected to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.

Key Dates

Recommendation

Keywords

Atara Biotherapeutics, ATRA, Form 4, SEC filing, Restricted Stock Units, RSU, Director compensation, Insider transaction, Equity grant, Pascal Touchon